116-02-9

应用筛选条件

关键词:'116-02-9'

显示 1-5 共 5 条结果关于 "116-02-9" 范围论文

Occurrence of nitro and non-nitro benzenoid musk compounds in human adipose tissue.

S Müller et al.

Chemosphere, 33(1), 17-28 (1996-07-01)

Nitro benzenoid musk compounds (Musk tibetene [CAS no. 145-39-1], Musk ambrette [83-66-9], Musk moskene [116-66-5], Musk ketone [81-14-1] and Musk xylene [81-15-2]) and non-nitro benzenoid musks (Celestolide [13171-00-1], Galaxolide [1222-05-5]) and Fixolide [1506-02-1] [21445-77-7] were analysed in 15 human adipose

Although divergent in residues of the peptide binding site, conserved chimpanzee Patr-AL and polymorphic human HLA-A*02 have overlapping peptide-binding repertoires.

Michael Gleimer et al.

Journal of immunology (Baltimore, Md. : 1950), 186(3), 1575-1588 (2011-01-07)

Patr-AL is an expressed, non-polymorphic MHC class I gene carried by ∼50% of chimpanzee MHC haplotypes. Comparing Patr-AL(+) and Patr-AL(-) haplotypes showed Patr-AL defines a unique 125-kb genomic block flanked by blocks containing classical Patr-A and pseudogene Patr-H. Orthologous to

Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations.

K D Wenstrom et al.

American journal of obstetrics and gynecology, 184(5), 806-812 (2001-04-17)

The aim of this study was determine whether the cytosine-to-thymine mutation at base 677 of the gene for methylenetetrahydrofolate reductase (C677T MTHFR ), which has been associated with neural tube defects, is also associated with congenital cardiac malformations. Amniotic fluid

The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.

Roni Nielsen et al.

Diabetes, obesity & metabolism, 22(11), 2141-2150 (2020-07-07)

To assess the effect of liraglutide, a glucagon-like peptide-1 receptor agonist, on urinary sodium excretion as well as on circulating adrenomedullin and copeptin levels in patients with type 2 diabetes (T2D). In the LIVE study, patients (n = 241) with

Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma.

Paul M Weinberger et al.

Archives of otolaryngology--head & neck surgery, 133(5), 503-510 (2007-05-23)

To characterize the localization of galectin-3 in benign and malignant thyroid neoplasms and to correlate this with alterations in beta-catenin and cyclin D1 expression. Immunohistochemical study of 116 paraffin-embedded archival specimens from 113 patients who had undergone thyroidectomy and tissue

1/1